Scholar Rock Holding Corporation (SRRK) and Reata Pharmaceuticals Inc. (NASDAQ:RETA) Contrasting side by side

Scholar Rock Holding Corporation (NASDAQ:SRRK) and Reata Pharmaceuticals Inc. (NASDAQ:RETA) compete with each other in the Biotechnology sector. We will analyze and contrast their profitability, analyst recommendations, risk, dividends, institutional ownership, earnings and valuation.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Scholar Rock Holding Corporation N/A 0.00 42.82M -1.74 0.00
Reata Pharmaceuticals Inc. 53.96M 47.45 71.64M -2.64 0.00

Table 1 showcases the gross revenue, earnings per share and valuation of Scholar Rock Holding Corporation and Reata Pharmaceuticals Inc.

Profitability

Table 2 has Scholar Rock Holding Corporation and Reata Pharmaceuticals Inc.’s return on equity, return on assets and net margins.

Net Margins Return on Equity Return on Assets
Scholar Rock Holding Corporation 0.00% 0% 0%
Reata Pharmaceuticals Inc. -132.77% 68.2% -34.6%

Liquidity

The Current Ratio of Scholar Rock Holding Corporation is 18.4 while its Quick Ratio stands at 18.4. The Current Ratio of rival Reata Pharmaceuticals Inc. is 6 and its Quick Ratio is has 6. Scholar Rock Holding Corporation is better equipped to clear short and long-term obligations than Reata Pharmaceuticals Inc.

Insider & Institutional Ownership

Institutional investors owned 51% of Scholar Rock Holding Corporation shares and 68% of Reata Pharmaceuticals Inc. shares. About 19.6% of Scholar Rock Holding Corporation’s share are owned by insiders. Comparatively, Reata Pharmaceuticals Inc. has 3.9% of it’s share owned by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Scholar Rock Holding Corporation 5.3% 4.74% 1.02% 48.18% 0% 65.48%
Reata Pharmaceuticals Inc. -5.68% -16.44% -28.5% 59.68% 127.24% 110.31%

For the past year Scholar Rock Holding Corporation’s stock price has smaller growth than Reata Pharmaceuticals Inc.

Summary

Scholar Rock Holding Corporation beats Reata Pharmaceuticals Inc. on 5 of the 9 factors.

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of various medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company is developing its lead antibody product candidate, SRK-015, a first-in-class inhibitor of the activation of myostatin that is in clinical development stage for the treatment of spinal muscular atrophy. It is also developing various product candidates for a range of serious diseases, including other neuromuscular disorders, cancer, fibrosis, and anemia. The company was founded in 2012 and is based in Cambridge, Massachusetts.

Reata Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on identifying, developing, and commercializing product candidates for patients with rare and life-threatening diseases by targeting molecular pathways that regulate cellular metabolism and inflammation. Its lead product candidates include Bardoxolone methyl, which is in Phase III clinical trial for the treatment of pulmonary arterial hypertension and associated with connective tissue disease, as well as in Phase II clinical trial for the treatment of pulmonary hypertension due to interstitial lung disease and pulmonary arterial hypertension; and Omaveloxolone that is in Phase II clinical trial for the treatment of FriedreichÂ’s ataxia, mitochondrial myopathies, and metastatic melanoma. The company was formerly known as Reata Discovery, Inc. and changed its name to Reata Pharmaceuticals, Inc. in May 2005. The company was founded in 2002 and is headquartered in Irving, Texas.